Publication | Closed Access

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

First-line TherapyMedicineCancer ManagementPharmacologyColorectal CancerMetastatic Colorectal CancerMolecular OncologyCancer TreatmentOncologyRadiation OncologyCancer Research